Takeda Pharmaceutical Company Limited
TKPHFOTCHealthcare● Active
$32.60
+$2.13(+6.99%)
Market Cap$51.5B
P/E Ratio—
52W High$39.2
52W Low$26.33
Takeda Pharmaceutical Company Limited (TKPHF) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TKPHF · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.193T | $0.108T | $0.144T | $0.317T | $0.230T |
| Depreciation & Amort. | $0.726T | $0.761T | $0.728T | $0.664T | $0.583T |
| Stock-Based Comp. | $0.000T | $0.073T | $0.071T | $0.061T | $0.043T |
| Change in Working Capital | ($0.251T) | ($0.059T) | ($0.256T) | ($0.025T) | $0.099T |
| Net Cash from Operations | $0.945T | $1.057T | $0.716T | $0.977T | $1.123T |
| Investing Activities | |||||
| Capital Expenditure | ($0.177T) | ($0.380T) | ($0.481T) | ($0.634T) | ($0.186T) |
| Purchases of Investments | ($0.017T) | ($0.111T) | ($0.040T) | ($0.010T) | ($0.008T) |
| Sales of Investments | $0.008T | $0.029T | $0.008T | $0.022T | $0.017T |
| Net Cash from Investing | ($0.390T) | ($0.367T) | ($0.464T) | ($0.607T) | ($0.198T) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.052T) | ($0.052T) | ($0.002T) | ($0.027T) | ($0.078T) |
| Dividends Paid | ($0.314T) | ($0.302T) | ($0.287T) | ($0.279T) | ($0.284T) |
| Debt Issued / Repaid | $0.044T | ($0.314T) | $0.002T | ($0.325T) | ($0.600T) |
| Net Cash from Financing | ($0.378T) | ($0.751T) | ($0.354T) | ($0.709T) | ($1.070T) |
| Free Cash Flow | |||||
| Free Cash Flow | $0.768T | $0.678T | $0.236T | $0.343T | $0.937T |
| FCF Margin %(computed) | 16.93% | 14.79% | 5.53% | 8.53% | 26.26% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · JPY · T
Explore more Takeda Pharmaceutical Company Limited data
About Takeda Pharmaceutical Company Limited (TKPHF) Cash Flow Statement
Takeda Pharmaceutical Company Limited generated operating cash flow of $944.62B and free cash flow of $767.51B for 2026 — a FCF margin of 16.93%. Capital expenditure was ($177.11B).
Frequently asked questions
TKPHF · 4 questionsTakeda Pharmaceutical Company Limited generated free cash flow of $767.51B for 2026, up 13.3% year-over-year.
TKPHF free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10